Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that shows high levels of a protein called folate receptor alpha (FRα) on the tumour cells.
• People whose tumour has been tested and confirmed as "FRα high" using a specific approved laboratory test (meaning at least 75% of tumour cells show a certain level of this protein).
• People who have a BRCA gene mutation (either in the tumour or inherited) must have already received a type of treatment called a PARP inhibitor before joining.
• People who have finished their most recent cancer treatment at least 4 weeks (or 5 half-lives of the drug, whichever is shorter) before starting the trial drug, and have finished any targeted radiation at least 2 weeks before starting.
• People who have recovered from side effects of previous treatments, with any remaining side effects being mild (Grade 1 or back to their normal baseline) — hair loss is the one exception.
• Women who could become pregnant must agree to use highly effective birth control during the trial and for at least 7 months after the last dose, and must have a negative pregnancy test taken within 4 days before starting the trial drug.

Who may not be able to join:

• People whose ovarian tumour is classified as "borderline," non-epithelial, or a mixed type that includes borderline or non-epithelial features.
• People whose cancer did not respond to, or got worse within 3 months of finishing, their first course of platinum-based chemotherapy.
• People who have moderate to severe nerve damage (greater than Grade 1 peripheral neuropathy), causing symptoms such as numbness, tingling, or pain in the hands or feet.
• People with significant active or long-term eye conditions, such as corneal disease, a history of corneal transplant, inflammatory eye conditions, uncontrolled glaucoma, active diabetic eye disease affecting the central vision, macular degeneration treated within the last 90 days, swelling of the optic nerve, vision worse than 20/70 in either eye, or vision in only one eye.
• People who are currently using, or have used within 5 weeks before starting the trial, corticosteroid or vessel-constricting eye drops.
• People who have previously been treated with the trial drug (MIRV/mirvetuximab soravtansine) or any other treatment that specifically targets the FRα protein.

Important: Always verify eligibility with the trial site directly before applying.